Morgan Stanley & Co. LLC recently announced the acquisition of new stake in AIM ImmunoTech Inc. (AMEX:AIM). This fresh investment now brings its stake to 1.45% valued currently at $1.38 million. In addition, BlackRock Fund Advisors raised its holdings by 0.46 million to 0.47 million shares. And The Vanguard Group, Inc. has lifted its position by 306.34% or 0.27 million shares – to 0.35 million shares.

With over 1.31 million AIM ImmunoTech Inc. (AIM) shares trading Friday and a closing price of $2.39 on the day, the dollar volume was approximately $3.14 million. The shares have shown a negative weekly performance of -0.42% and its price on 08/28/20 lost nearly -1.65%. Currently, there are 39.69M common shares owned by the public and among those 39.26M shares have been available to trade.

An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 3 analysts who have offered their price forecasts for AIM have a consensus price objective of $6.25. The analysts have set the share’s price value over the next 12 months at a high of $7.25 and a low of $5.00 should the stock experience a downside. Incidentally, analysts’ outlook for the AIM ImmunoTech Inc. stock is 2.00 for the next 12 months. But an upside of 67.03% will see the stock hit the forecast high price target while mean target price for the stock is $6.50.

Insiders at the company have transacted a total of 33 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 33 of these insider trades were purchases, accounting for 269,578 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.

The top 3 mutual fund holders in AIM ImmunoTech Inc. are Vanguard Extended Market Index Fu, Fidelity Extended Market Index Fu, and iShares Tr. – Micro Cap ETF. Vanguard Extended Market Index Fu owns 0.39 million shares of the company’s stock, all valued at over $1.13 million. The company bought an additional 36100.0 shares recently to bring their total holdings to about 1.19% of the shares outstanding. iShares Tr. – Micro Cap ETF now owns shares totaling to 0.21% of the shares outstanding.

Shares of AIM ImmunoTech Inc. (AMEX: AIM) opened at $2.21, down -$0.22 from a prior closing price of $2.43. However, the script later closed the day at $2.39, down -1.65%. The company’s stock has a 5-day price change of -0.42% and -14.03% over the past three months. AIM shares are trading 339.34% year to date (YTD), with the 12-month market performance up to 32.04% higher. It has a 12-month low price of $0.38 and touched a high of $7.11 over the same period. Currently, 1.31 million shares have been traded, compared to an average intraday trading volume of 5.79 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -7.94%, -11.19%, and 26.28% respectively.

Institutional ownership of AIM ImmunoTech Inc. (AMEX: AIM) shares accounts for 4.70% of the company’s 39.69M shares outstanding. Mutual fund holders own 1.87%, while other institutional holders and individual stakeholders account for 3.87% and 1.23% respectively.

It has a market capitalization of $96.39M and a beta (3y monthly) value of -0.95. The earnings-per-share (ttm) stands at -$1.49. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.37% over the week and 9.14% over the month.

Analysts forecast that AIM ImmunoTech Inc. (AIM) will achieve an EPS of -$0.08 for the current quarter, -$0.08 for the next quarter and -$0.37 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.1 while analysts give the company a high EPS estimate of -$0.07. Comparatively, EPS for the current quarter was -$1.13 a year ago. Earnings per share for the fiscal year are expected to increase by 73.20%, and 14.00% over the next financial year. EPS should shrink at an annualized rate of 25.00% over the next five years, compared to 44.30% over the past 5-year period.

If you are looking to buy this stock, then you may note that the average analyst recommendation by 3 brokerage firm advisors rate AIM ImmunoTech Inc. (AIM) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 3 Wall Street analysts polled rate the stock as a buy, while 0 of the 3 advise that investors “hold,” and 0 rated it as a “Sell.”